Soleno Therapeutics Stock Working Capital
| SLNO Stock | USD 52.71 3.13 5.61% |
Soleno Therapeutics fundamentals help investors to digest information that contributes to Soleno Therapeutics' financial success or failures. It also enables traders to predict the movement of Soleno Stock. The fundamental analysis module provides a way to measure Soleno Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Soleno Therapeutics stock.
| Last Reported | Projected for Next Year | ||
| Net Working Capital | 159.9 M | 167.8 M | |
| Change In Working Capital | 2.9 M | 3.1 M |
Soleno | Working Capital |
Soleno Therapeutics Company Working Capital Analysis
Soleno Therapeutics' Working Capital is a measure of company efficiency and operating liquidity. The working capital is usually calculated by subtracting Current Liabilities from Current Assets. It is an important indicator of the firm ability to continue its normal operations without additional debt obligations. .
More About Working Capital | All Equity Analysis
Working Capital | = | Current Assets | - | Current Liabilities |
Current Soleno Therapeutics Working Capital | 159.85 M |
Most of Soleno Therapeutics' fundamental indicators, such as Working Capital, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Soleno Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Soleno Working Capital Driver Correlations
Understanding the fundamental principles of building solid financial models for Soleno Therapeutics is extremely important. It helps to project a fair market value of Soleno Stock properly, considering its historical fundamentals such as Working Capital. Since Soleno Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Soleno Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Soleno Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Working Capital can be positive or negative, depending on how much of current debt the company is carrying on its balance sheet. In general terms, companies that have a lot of working capital will experience more growth in the near future since they can expand and improve their operations using existing resources. On the other hand, companies with small or negative working capital may lack the funds necessary for growth or future operation. Working Capital also shows if the company has sufficient liquid resources to satisfy short-term liabilities and operational expenses.
| Competition |
Soleno Capital Surpluse
Capital Surpluse |
|
Based on the company's disclosures, Soleno Therapeutics has a Working Capital of 159.85 M. This is 62.45% lower than that of the Biotechnology sector and 70.32% lower than that of the Health Care industry. The working capital for all United States stocks is 89.19% higher than that of the company.
Soleno Working Capital Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Soleno Therapeutics' direct or indirect competition against its Working Capital to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Soleno Therapeutics could also be used in its relative valuation, which is a method of valuing Soleno Therapeutics by comparing valuation metrics of similar companies.Soleno Therapeutics is currently under evaluation in working capital category among its peers.
Soleno Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Soleno Therapeutics from analyzing Soleno Therapeutics' financial statements. These drivers represent accounts that assess Soleno Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Soleno Therapeutics' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 100.4M | 120.9M | 32.7M | 16.6M | 15.0M | 14.2M | |
| Enterprise Value | 80.0M | 71.8M | 11.9M | 2.2M | 2.0M | 1.9M |
Soleno Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Soleno Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Soleno Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Soleno Fundamentals
| Return On Equity | -0.91 | ||||
| Return On Asset | -0.48 | ||||
| Current Valuation | 2.02 B | ||||
| Shares Outstanding | 43.12 M | ||||
| Shares Owned By Insiders | 3.04 % | ||||
| Shares Owned By Institutions | 96.96 % | ||||
| Number Of Shares Shorted | 4.74 M | ||||
| Price To Earning | (3.71) X | ||||
| Price To Book | 8.59 X | ||||
| EBITDA | (37.03 M) | ||||
| Net Income | (38.99 M) | ||||
| Cash And Equivalents | 24.07 M | ||||
| Cash Per Share | 2.97 X | ||||
| Total Debt | 403 K | ||||
| Debt To Equity | 0.02 % | ||||
| Current Ratio | 3.43 X | ||||
| Book Value Per Share | 6.45 X | ||||
| Cash Flow From Operations | (24.94 M) | ||||
| Short Ratio | 8.87 X | ||||
| Earnings Per Share | (2.79) X | ||||
| Target Price | 74.25 | ||||
| Number Of Employees | 33 | ||||
| Beta | -1.44 | ||||
| Market Capitalization | 2.41 B | ||||
| Total Asset | 180.69 M | ||||
| Retained Earnings | (276.41 M) | ||||
| Working Capital | 159.85 M | ||||
| Net Asset | 180.69 M |
About Soleno Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Soleno Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Soleno Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Soleno Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Soleno Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Soleno Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Soleno Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Soleno Stock
| 0.73 | ESPR | Esperion Therapeutics Buyout Trend | PairCorr |
| 0.72 | EWTX | Edgewise Therapeutics | PairCorr |
| 0.64 | BHC | Bausch Health Companies | PairCorr |
Moving against Soleno Stock
| 0.71 | TAK | Takeda Pharmaceutical | PairCorr |
| 0.7 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
| 0.67 | HLN | Haleon plc | PairCorr |
| 0.65 | RDY | Dr Reddys Laboratories | PairCorr |
| 0.6 | ELAN | Elanco Animal Health | PairCorr |
The ability to find closely correlated positions to Soleno Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Soleno Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Soleno Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Soleno Therapeutics to buy it.
The correlation of Soleno Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Soleno Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Soleno Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Soleno Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Soleno Therapeutics Piotroski F Score and Soleno Therapeutics Altman Z Score analysis. To learn how to invest in Soleno Stock, please use our How to Invest in Soleno Therapeutics guide.You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Soleno Therapeutics. If investors know Soleno will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Soleno Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.79) | Return On Assets (0.48) | Return On Equity (0.91) |
The market value of Soleno Therapeutics is measured differently than its book value, which is the value of Soleno that is recorded on the company's balance sheet. Investors also form their own opinion of Soleno Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Soleno Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Soleno Therapeutics' market value can be influenced by many factors that don't directly affect Soleno Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Soleno Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Soleno Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Soleno Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.